Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for NS 304

    Client Email Product

    NS 304

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Related ProductsRelated Products
    API SUPPLIERS
    API Suppliers

    API Suppliers

    26
    US DMFs Filed

    US DMFs Filed

    9
    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    4
    Other Suppliers

    Other Suppliers

    17
    API REF. PRICE (USD / KG)
    278,087

    API Market Place

    3
    INTERMEDIATES
    3
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    39
    Europe

    Europe

    18
    Canada

    Canada

    8
    Australia

    Australia

    20
    South Africa

    South Africa

    9
    Uploaded Dossiers

    Uploaded Dossiers

    0

    GLOBAL SALES (USD Million)

    U.S. Medicaid

    2,189.00

    Annual Reports

    663.00

    FDF Market Place

    2
    EXCIPIENTS
    113
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    52

    USFDA Exclusivities

    0

    DIGITAL CONTENT

    Blog #PharmaFlow

    1

    News

    22
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    Full View ScreenFull Screen View
    Cipla`s Generic Selexipag Receives Approval in the U.S.
    Cipla`s Generic Selexipag Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216607

    FDA
    11 Mar 2024
    Share Share
    Zydus' Generic Selexipag Receives Approval in the U.S.
    Zydus' Generic Selexipag Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214302

    FDA
    21 Dec 2022
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Uptravi (Selexipag)
    FDA Confirms Paragraph IV Patent Litigation for Uptravi (Selexipag)

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-uptravi-selexipag-37134.pdf

    FDA
    22 Sep 2022
    Share Share
    Zydus receives tentative approval from US FDA for Selexipag tablets
    Zydus receives tentative approval from US FDA for Selexipag tablets

    https://www.expresspharma.in/zydus-receives-tentative-approval-from-us-fda-for-selexipag-tablets/

    EXPRESS PHARMA
    06 May 2022
    Share Share
    SPIL's Generic Amphotericin B Receives Approval in the U.S.
    SPIL's Generic Amphotericin B Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212514

    FDA
    13 Dec 2021
    Share Share
    Alembic Pharm's Generic Selexipag Receives Approval in the U.S.
    Alembic Pharm's Generic Selexipag Receives Approval in the U.S.

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214414

    FDA
    07 Dec 2021
    Share Share
    New Data Demonstrate the Benefits of Early Use of UPTRAVI® (selexipag) in PAH
    New Data Demonstrate the Benefits of Early Use of UPTRAVI® (selexipag) in PAH

    https://www.businesswire.com/news/home/20210829005012/en

    BUSINESSWIRE
    30 Aug 2021
    Share Share
    TRITON Phase 3b Study Results Presented at the European Society of Cardiology
    TRITON Phase 3b Study Results Presented at the European Society of Cardiology

    https://www.businesswire.com/news/home/20200829005001/en/TRITON-Phase-3b-Study-Results-Presented-European#:~:text=In%20the%20TRITON%20trial%2C%20both,difference%20observed%20between%20both%20groups.

    BUSINESSWIRE
    31 Aug 2020
    Share Share
    FDA Confirms Paragraph IV Patent Challenge of Uptravi 207947 (Selexipag) Tablets
    FDA Confirms Paragraph IV Patent Challenge of Uptravi 207947 (Selexipag) Tablets

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-uptravi-207947-selexipag-tablets-1582965936.pdf

    FDA
    29 Feb 2020
    Share Share
    NHS England to fund Actelion's Uptravi
    NHS England to fund Actelion's Uptravi

    http://www.pharmatimes.com/news/nhs_england_to_fund_actelions_uptravi_1273628

    Anna Smith
    03 Jan 2019
    Share Share
    United Therapeutics pays $800M-plus to grab Arena’s PhIII PAH drug
    United Therapeutics pays $800M-plus to grab Arena’s PhIII PAH drug

    https://endpts.com/united-therapeutics-pays-800m-plus-to-grab-arenas-phiii-pah-drug/

    ENDPTS
    16 Nov 2018
    Share Share
    PAH patients in England denied access to Actelion’s Uptravi on NHS
    PAH patients in England denied access to Actelion’s Uptravi on NHS

    http://www.pharmatimes.com/news/pah_patients_in_england_denied_access_to_actelions_uptravi_on_nhs_1243567

    Selina McKee PHARMA TIMES
    09 Jul 2018
    Share Share
    Five therapies endorsed for use on NHS Scotland
    Five therapies endorsed for use on NHS Scotland

    http://www.pharmatimes.com/news/five_therapies_endorsed_for_use_on_nhs_scotland_1234655

    Selina McKee PARMA TIMES
    08 May 2018
    Share Share
    Meeting highlights from the PV Risk Assessment Committee (PRAC) 3-6 April 2017
    Meeting highlights from the PV Risk Assessment Committee (PRAC) 3-6 April 2017

    http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2017/04/news_detail_002724.jsp&mid=WC0b01ac058004d5c1

    EMA
    05 May 2017
    Share Share
    EMA Completes Postmarket Safety Review of Uptravi
    EMA Completes Postmarket Safety Review of Uptravi

    http://www.raps.org/Regulatory-Focus/News/2017/04/07/27298/EMA-Completes-Postmarket-Safety-Review-of-Uptravi/?utm_source=Email&utm_medium=Informz&utm_campaign=Informz-Emails

    Michael Mezher RAPS
    08 Apr 2017
    Share Share
    EMA panel recommends that use of Actelion's Uptravi may continue
    EMA panel recommends that use of Actelion's Uptravi may continue

    http://www.reuters.com/article/us-actelion-johnson-johnson-uptravi-idUSKBN15P1KU

    John Miller REUTERS
    11 Feb 2017
    Share Share
    Johnson & Johnson May Never Recoup Its Costs to Buy Actelion
    Johnson & Johnson May Never Recoup Its Costs to Buy Actelion

    http://www.fool.com/investing/2017/01/27/johnson-johnson-may-never-recoup-its-costs-to-buy.aspx

    Sean Williams MOTLEY FOOL
    28 Jan 2017
    Share Share
    Actelion Fails Key PhIII, but Investors Brush it off as J&J Megadeal Draws Near
    Actelion Fails Key PhIII, but Investors Brush it off as J&J Megadeal Draws Near

    http://www.fiercepharma.com/pharma/actelion-fails-key-phase-3-but-investors-brush-it-off-as-j-j-mega-deal-draws-near

    A Weintraub FIERCE PHARMA
    24 Jan 2017
    Share Share
    J&J Discussing Breaking up Actelion in an Acquisition
    J&J Discussing Breaking up Actelion in an Acquisition

    http://www.reuters.com/article/us-actelion-m-a-johnson-johnson-exclusiv-idUSKBN14I1HX

    Carl O'Donnell REUTERS
    30 Dec 2016
    Share Share
    Actelion's ambitious independent-minded CEO will drive up takeover price
    Actelion's ambitious independent-minded CEO will drive up takeover price

    http://www.reuters.com/article/us-actelion-johnson-johnson-m-a-idUSKBN13N179

    John Miller REUTERS
    28 Nov 2016
    Share Share
    Actelion hikes core profit guidance after strong first-half
    Actelion hikes core profit guidance after strong first-half

    http://www.reuters.com/article/us-actelion-results-idUSKCN1010G4

    Maria Sheahan REUTERS
    21 Jul 2016
    Share Share
    European approval for Actelion's Uptravi in PAH
    European approval for Actelion's Uptravi in PAH

    http://pharmatimes.com/Article/16-05-17/European_approval_for_Actelion_s_Uptravi_in_PAH.aspx

    Selina McKee PHARMATIMES
    17 May 2016
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search